



Date: 13/08/2021

To,
The Board of Directors,
Ishita Drugs & Industries Limited,
Ahmedabad.

LIMITED REVIEW REPORT

We have reviewed the accompanying of unaudited financial results of **ISHITA DRUGS AND INDUSTRIES LIMITED** for the period **01 April 2021 to 30 JUNE 2021** (The Statement) being submitted by the Company pursuant to the requirement of Regulation 33 of SEBI (Listing of Obligation and Disclosure Requirements) Regulation, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of **Interim financial information performed by the Independent auditor of the entity issued by the Institute of Chartered Accountants of India**. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with Indian accounting standards prescribe under section 133 of companies Act, 2013 read with relevant rules issued there under and another recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of SEBI (Listing Of Obligation and Disclosure Requirements) Regulation, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For and on behalf of
JAYMIN SHAH & ASSOCIATES

Chartered Accountants

CA Mayank Sancheti

M No. :170863

Date: 13/08/2021

Place: Ahmedabad

UDIN: **21170863AAAADR7164**



Corp. Office : 410-411, Lilamani Corporate Heights, Opp. Ramapir Brts Bus Stand, Nr. Ozone Aangan, New Wadaj, Ahmedabad - 380013, Gujarat
Branch Office : 504, Palladium Business Hub, Above Pantaloons, Opp. 4D Mall - PVR Cinema, Visat-Gandhinagar Highway, Ahmedabad-382424

CA Mayank Sancheti +91 8000331632 / 7048685472
Deepak Surana +91 9429913706
GSTIN : 24AAOFJ1119R1ZY

camayanksancheti@gmail.com
dpaksurana4u@gmail.com

ISHITA DRUGS AND INDUSTRIES LIMITED

CIN: L24231GJ1992PLC017054

Registered Office: Survey No. 179/1, Village : Vasna-Iyava, Ta. Sanand

Ahmedabad – 382170

Website: www.ishitadrugs.com

Contact: +91 7226995613

Unaudited Financial Results for the Quarter Ended June 30, 2021



Amount in Lacs except Per Share data

Particulars	Figures for 3 Months Ended	Figures for Preceding 3 Months Ended	Figures for Corresponding 3 Months in the previous Year Ended	Figures for the previous year Ended
	Un-audited	Audited	Un-audited	Audited
	30-06-21	31-Mar-21	30-Jun-20	31-Mar-21
1 INCOME				
Revenue from Operations	288.928	401.892	230.401	1394.901
Other Income	3.798	26.267	0.380	31.357
Total Income	292.726	428.159	230.781	1426.258
2 EXPENSES				
(a) Cost of Material Consumed	197.651	226.267	153.916	956.397
(b) Purchase of Stock-In-Trade	2.900	49.050	1.469	63.183
(c) Changes in Inventories of Finished Goods, Work-In-Progress and Stock-In-Trade	(4.651)	6.964	(2.597)	9.130
(d) Employee Benefit Expense	26.958	30.113	25.611	109.743
(e) Finance Cost	0.451	1.465	0.567	3.163
(f) Depreciation, Depletion and Amortisation Expense	3.654	1.304	4.437	14.614
(g) Other Expense	48.151	58.010	35.316	164.654
Total Other Expenses	48.151	58.010	35.316	164.654
Total Expenses	275.114	373.173	218.719	1320.884
3 Total Profit before Exceptional Items and Tax	17.612	54.986	12.061	105.374
4 Exceptional Items	0.000	0.000	0.000	0.000
5 Total Profit before Tax	17.612	54.986	12.061	105.374
6 Tax Expense				
7 Current Tax	4.000	10.500	3.000	23.000
8 Deferred Tax	0.000	(0.580)	0.000	(0.580)
9 Total Tax Expenses	4.000	9.920	3.000	22.420
10 Net Movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement		0.000	0.000	0.000
11 Net Profit Loss for the period from continuing operations	13.612	45.066	9.061	82.954
12 Profit / (Loss) from discontinued operations before tax	0.000	0.000	0.000	0.000
13 Tax Expenses of discontinued operations	0.000	0.000	0.000	0.000
14 Net Profit / (Loss) from discontinued operations after tax	0.000	0.000	0.000	0.000

Jaydin




15	Share of Profit / (Loss) of associates and joint ventures accounted for using equity method	0.000	0.000	0.000	0.000
16	Total Profit / (Loss) for the period	13.612	45.066	9.061	82.954
17	Other Comprehensive Income net of Taxes	0.000	0.000	0.000	0.000
18	Total Comprehensive Income for the Period	13.612	45.066	9.061	82.954
19	Total profit or loss attributable to				
	Profit or loss, attributable to owners of parents	0.000	0.000	0.000	0.000
	Total Profit or loss, attributable to non-controlling interests	0.000	0.000	0.000	0.000
20	Total comprehensive income for the period attributable to				
	Comprehensive Income for the period attributable to the owners of parents	0.000	0.000	0.000	0.000
	Total comprehensive income for the period attributable to the owners of parent non-controlling interests	0.000	0.000	0.000	0.000
21	Details of Equity Share Capital				
	Paid-Up Equity Share Capital	299.030	299.030	299.030	299.030
	Face Value of Equity Share Capital	10.000	10.000	10.000	10.000
22	Details of Debt Securities				
	Paid-Up Debt Capital	0.000	0.000	0.000	0.000
	Face Value of Debt Securities	0.000	0.000	0.000	0.000
23	Reserves Excluding Revaluation Reserves	0.000	0.000	0.000	0.000
24	Debenture Redemption Reserve	0.000	0.000	0.000	0.000
25	Earnings Per Share				
(i)	Earnings Per Share for continuing operations				
	Basic Earnings / (Loss) per share from continuing operations	0.455	1.507	0.303	2.774
	Diluted Earnings / (Loss) per share from continuing operations	0.455	1.507	0.303	2.774
(ii)	Earnings Per Share for discontinued operations				
	Basic Earnings / (Loss) per share from discontinued operations	0.000	0.000	0.000	0.000
	Diluted Earnings / (Loss) per share from discontinued operations	0.000	0.000	0.000	0.000
(iii)	Earnings per Equity Share				
	Basic Earnings / (Loss) per share from continuing and discontinued operations	0.455	1.507	0.303	2.774
	Diluted Earnings / (Loss) per share from continuing and discontinued operations	0.455	1.507	0.303	2.774
26	Debt Equity Ratio	0.000	0.000	0.000	0.000
27	Debt Service Coverage Ratio	0.000	0.000	0.000	0.000
28	Interest Service Coverage Ratio	0.000	0.000	0.000	0.000

NOTES

1. The above Financial Results were reviewed by the Audit Committee and thereafter were approved and taken on record by the Board of Directors in their meeting held on August 13, 2021
2. The Limited Review of the results has been completed by the Statutory Auditors of the Company.
3. As per Indian Accounting Standard (IndAS) "Operating Segment", the Company's business falls within a single business segment viz. "Pharmaceutical Business".
4. The financial results for the quarter ended 30th June, 2021 are Ind AS compliant. The management has exercised necessary due diligence to ensure that the financial results give a true and fair view. This information has not been subjected to limited review or audit.
5. Previous quarter's amounts have been re-grouped/re-classified, wherever considered necessary to make them comparable with those of the current quarter.
6. Results are available at Company's website www.ishitadrugs.com and also at www.bseindia.com.

For, ISHITA DRUGS AND INDUSTRIES LIMITED

Place **Ahmedabad**Date **13-Aug-21****JAGDISH AGRAWAL**
MANAGING DIRECTOR

DIN: 01031687